Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID:...
The partnership will focus on Crescent’s PD-1/VEGF inhibitor CR-001 and Kelun-Biotech’s SKB105, both of which...
TURKU, FI / ACCESS Newswire / December 1, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN),...
OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial) become available across Europe as...
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the...
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane”...
Six months after receiving a surprise rejection due to what the FDA called “lack of...
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of...
With new UK clinical trial rules landing in 2026, the EU Biotech Act on the...
Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility...
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential...
– The sunbird αSyn™ assay accurately classified Parkinson’s disease-positive blood samples with 81% accuracy through...
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company's...
This year has seen the approval of several first-in-class therapies for HAE, but in a...
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)...